The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet?

被引：28

作者：

Bronte, Giuseppe ^{[1
]}

Incorvaia, Lorena ^{[1
]}

Rizzo, Sergio ^{[1
]}

Passiglia, Francesco ^{[1
]}

Galvano, Antonio ^{[1
]}

Rizzo, Fabio ^{[1
]}

Rolfo, Christian ^{[2
,3
]}

Fanale, Daniele ^{[1
]}

Listi, Angela ^{[1
]}

Natoli, Clara ^{[4
]}

Bazan, Viviana ^{[1
]}

Russo, Antonio ^{[1
]}

机构：

[1] Univ Palermo, Dept Surg Oncol & Oral Sci, Sect Med Oncol, Palermo, Italy

[2] Univ Antwerp Hosp, Phase Early Clin Trials Unit 1, Dept Oncol, Edegem, Belgium

[3] Univ Antwerp Hosp, Multidisciplinary Oncol Ctr Antwerp, Edegem, Belgium

[4] Univ G DAnnunzio, Dept Med Oral & Biotechnol Sci, Chieti, Italy

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2016年 / 107卷

关键词：

Mesothelioma; Pleura; Targeted therapy; Resistance; GROWTH-FACTOR RECEPTOR; HISTONE DEACETYLASE INHIBITORS; TRANSCRIPTION FACTOR FOXK2; II CLINICAL-TRIAL; CELL-CYCLE ARREST; PHASE-II; IMATINIB MESYLATE; TUMOR-SUPPRESSOR; 2ND-LINE TREATMENT; PLUS BEVACIZUMAB;

D O I：

10.1016/j.critrevonc.2016.08.011

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Malignant pleural mesothelioma (MPM) is an aggressive tumor of the pleura with a poor prognosis. The most active first-line regimens are platinum compounds and pemetrexed. There is no standard second-line treatment in MPM. Advances in the understanding of tumor molecular biology have led to the development of several targeted treatments, which have been evaluated in clinical trials. Unfortunately none of the explored targeted treatments can currently be recommended as routine treatment in MPM. We reviewed the biological pathways involved in MPM, the clinical trials about targeted therapy, and possible related mechanisms of resistance. We suggest that specific genetic markers are needed as targets of selective therapy. By this way the selection of patients based on the molecular profile may facilitate a therapeutic strategy that allows the use of the most appropriate drug for each patient. (C) 2016 Elsevier Ireland Ltd. All rights reserved.

引用

页码：20 / 32

页数：13

共 129 条

[1] Phase I and pharmacokinetic study of imatinib mesylate (Gleevec) and gemcitabine in patients with refractory solid tumors [J].